{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:31:11Z","timestamp":1778797871649,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T00:00:00Z","timestamp":1364256000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-230x-13-56","type":"journal-article","created":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T15:34:52Z","timestamp":1364312092000},"source":"Crossref","is-referenced-by-count":52,"title":["Association of a probiotic to a Helicobacter pylorieradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study"],"prefix":"10.1186","volume":"13","author":[{"given":"Tom\u00e1s","family":"Navarro-Rodriguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando Marcuz","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo Correa","family":"Barbuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rejane","family":"Mattar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquim Prado","family":"Moraes-Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maric\u00ea Nogueira","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina S","family":"Bogsan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e9cio","family":"Chinzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime Natan","family":"Eisig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,26]]},"reference":[{"key":"916_CR1","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1590\/S0004-28032005000200012","volume":"42","author":"LG Coelho","year":"2005","unstructured":"Coelho LG, Zaterka S: [Second Brazilian Consensus Conference on Helicobacter pylori infection]. Arq Gastroenterol. 2005, 42: 128-132.","journal-title":"Arq Gastroenterol"},{"key":"916_CR2","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1111\/j.1572-0241.2007.01393.x","volume":"102","author":"WD Chey","year":"2007","unstructured":"Chey WD, Wong BC: American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007, 102: 1808-1825. 10.1111\/j.1572-0241.2007.01393.x.","journal-title":"Am J Gastroenterol"},{"key":"916_CR3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","volume":"61","author":"P Malfertheiner","year":"2012","unstructured":"Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ: Management of Helicobacter pylori infection\u2013the Maastricht IV\/ Florence Consensus Report. Gut. 2012, 61: 646-664. 10.1136\/gutjnl-2012-302084.","journal-title":"Gut"},{"key":"916_CR4","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1572-0241.2008.01819.x","volume":"103","author":"NJ Talley","year":"2008","unstructured":"Talley NJ, Fock KM, Moayyedi P: Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol. 2008, 103: 510-514. 10.1111\/j.1572-0241.2008.01819.x.","journal-title":"Am J Gastroenterol"},{"key":"916_CR5","doi-asserted-by":"publisher","first-page":"186734","DOI":"10.5402\/2012\/186734","volume":"2012","author":"M Gasparetto","year":"2012","unstructured":"Gasparetto M, Pescarin M, Guariso G: Helicobacter pylori Eradication Therapy: Current Availabilities. ISRN Gastroenterol. 2012, 2012: 186734-","journal-title":"ISRN Gastroenterol"},{"key":"916_CR6","first-page":"505","volume":"88","author":"AF Cutler","year":"1993","unstructured":"Cutler AF, Schubert TT: Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol. 1993, 88: 505-509.","journal-title":"Am J Gastroenterol"},{"key":"916_CR7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1751-2980.2010.00445.x","volume":"11","author":"CS Qua","year":"2010","unstructured":"Qua CS, Manikam J, Goh KL: Efficacy of 1-week proton pump inhibitor triple therapy as first-line Helicobacter pylori eradication regime in Asian patients: is it still effective 10 years on?. J Dig Dis. 2010, 11: 244-248.","journal-title":"J Dig Dis"},{"key":"916_CR8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2165\/00002018-199309050-00004","volume":"9","author":"P Periti","year":"1993","unstructured":"Periti P, Mazzei T, Mini E, Novelli A: Adverse effects of macrolide antibacterials. Drug Saf. 1993, 9: 346-364. 10.2165\/00002018-199309050-00004.","journal-title":"Drug Saf"},{"key":"916_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/jac\/dkm111","volume":"60","author":"F Salvo","year":"2007","unstructured":"Salvo F, Polimeni G, Moretti U, Conforti A, Leone R, Leoni O, Motola D, Dusi G, Caputi AP: Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. J Antimicrob Chemother. 2007, 60: 121-126. 10.1093\/jac\/dkm111.","journal-title":"J Antimicrob Chemother"},{"key":"916_CR10","volume-title":"Cancer Causes Control","author":"C Porras","year":"2012","unstructured":"Porras C, Nodora J, Sexton R, Ferreccio C, Jimenez S, Dominguez RL, Cook P, Anderson G, Morgan DR, Baker LH, Greenberg ER, Herrero R: Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Cancer Causes Control. 2012, Available at http:\/\/link.springer.com\/content\/pdf\/10.1007%2Fs10552-012-0117-5"},{"key":"916_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1523-5378.2007.00474.x","volume":"12","author":"S Zaterka","year":"2007","unstructured":"Zaterka S, Eisig JN, Chinzon D, Rothstein W: Factors related to Helicobacter pylori prevalence in an adult population in Brazil. Helicobacter. 2007, 12: 82-88.","journal-title":"Helicobacter"},{"key":"916_CR12","first-page":"393","volume":"87","author":"ML Escobar-Pardo","year":"2011","unstructured":"Escobar-Pardo ML, de Godoy AP, Machado RS, Rodrigues D, Fagundes Neto U, Kawakami E: Prevalence of Helicobacter pylori infection and intestinal parasitosis in children of the Xingu Indian Reservation. J Pediatr (Rio J). 2011, 87: 393-398.","journal-title":"J Pediatr (Rio J)"},{"key":"916_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1590\/S1516-31802010000400002","volume":"128","author":"AC Miranda","year":"2010","unstructured":"Miranda AC, Machado RS, Silva EM, Kawakami E: Seroprevalence of Helicobacter pylori infection among children of low socioeconomic level in Sao Paulo. Sao Paulo Med J. 2010, 128: 187-191. 10.1590\/S1516-31802010000400002.","journal-title":"Sao Paulo Med J"},{"key":"916_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1523-5378.2010.00766.x","volume":"15","author":"VC Dattoli","year":"2010","unstructured":"Dattoli VC, Veiga RV, da Cunha SS, Pontes-de-Carvalho LC, Barreto ML, Alcantara-Neves NM: Seroprevalence and potential risk factors for Helicobacter pylori infection in Brazilian children. Helicobacter. 2010, 15: 273-278. 10.1111\/j.1523-5378.2010.00766.x.","journal-title":"Helicobacter"},{"key":"916_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1590\/S1413-86702005000500008","volume":"9","author":"MN Rodrigues","year":"2005","unstructured":"Rodrigues MN, Queiroz DM, Rodrigues RT, Rocha AM, Braga Neto MB, Braga LL: Helicobacter pylori infection in adults from a poor urban community in northeastern Brazil: demographic, lifestyle and environmental factors. Braz J Infect Dis. 2005, 9: 405-410. 10.1590\/S1413-86702005000500008.","journal-title":"Braz J Infect Dis"},{"key":"916_CR16","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1590\/S0034-89102005000500022","volume":"39","author":"MN Rodrigues","year":"2005","unstructured":"Rodrigues MN, Queiroz DM, Rodrigues RT, Rocha AM, Luz CR, Braga LL: Prevalence of Helicobacter pylori infection in Fortaleza, Northeastern Brazil. Rev Saude Publica. 2005, 39: 847-849. 10.1590\/S0034-89102005000500022.","journal-title":"Rev Saude Publica"},{"key":"916_CR17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S0035-9203(03)90063-0","volume":"97","author":"RP Almeida Cunha","year":"2003","unstructured":"Almeida Cunha RP, Alves FP, Rocha AM, Rocha GA, Camargo LM, Nogueira PO, Camargo EP, Queiroz DM: Prevalence and risk factors associated with Helicobacter pylori infection in native populations from Brazilian Western Amazon. Trans R Soc Trop Med Hyg. 2003, 97: 382-386. 10.1016\/S0035-9203(03)90063-0.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"916_CR18","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1128\/AAC.46.6.2021-2023.2002","volume":"46","author":"P Prazeres Magalhaes","year":"2002","unstructured":"Prazeres Magalhaes P, De Magalhaes Queiroz DM, Campos Barbosa DV, Aguiar Rocha G, Nogueira Mendes E, Santos A, Valle Correa PR, Camargos Rocha AM, Martins Teixeira L, Affonso de Oliveira C: Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil. Antimicrob Agents Chemother. 2002, 46: 2021-2023. 10.1128\/AAC.46.6.2021-2023.2002.","journal-title":"Antimicrob Agents Chemother"},{"key":"916_CR19","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1093\/jac\/dkr293","volume":"66","author":"M Oleastro","year":"2011","unstructured":"Oleastro M, Cabral J, Ramalho PM, Lemos PS, Paixao E, Benoliel J, Santos A, Lopes AI: Primary antibiotic resistance of Helicobacter pylori strains isolated from Portuguese children: a prospective multicentre study over a 10 year period. J Antimicrob Chemother. 2011, 66: 2308-2311. 10.1093\/jac\/dkr293.","journal-title":"J Antimicrob Chemother"},{"key":"916_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1523-5378.2011.00841.x","volume":"16","author":"KL Goh","year":"2011","unstructured":"Goh KL, Navaratnam P: High Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in Malaysia. Helicobacter. 2011, 16: 241-245. 10.1111\/j.1523-5378.2011.00841.x.","journal-title":"Helicobacter"},{"key":"916_CR21","first-page":"409","volume":"19","author":"V De Francesco","year":"2010","unstructured":"De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, Ierardi E, Zullo A: Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010, 19: 409-414.","journal-title":"J Gastrointestin Liver Dis"},{"key":"916_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1046\/j.1523-5378.2000.00011.x","volume":"5","author":"S Mendonca","year":"2000","unstructured":"Mendonca S, Ecclissato C, Sartori MS, Godoy AP, Guerzoni RA, Degger M, Pedrazzoli J: Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter. 2000, 5: 79-83. 10.1046\/j.1523-5378.2000.00011.x.","journal-title":"Helicobacter"},{"key":"916_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-230X-3-20","volume":"3","author":"AP Godoy","year":"2003","unstructured":"Godoy AP, Ribeiro ML, Benvengo YH, Vitiello L, Miranda Mde C, Mendonca S, Pedrazzoli J: Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates. BMC Gastroenterol. 2003, 3: 20-10.1186\/1471-230X-3-20.","journal-title":"BMC Gastroenterol"},{"key":"916_CR24","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3855\/jidc.911","volume":"4","author":"G Felga","year":"2010","unstructured":"Felga G, Silva FM, Barbuti RC, Navarro-Rodriguez T, Zaterka S, Eisig JN: Clarithromycin-based triple therapy for Helicobacter pylori treatment in peptic ulcer patients. J Infect Dev Ctries. 2010, 4: 712-716.","journal-title":"J Infect Dev Ctries"},{"key":"916_CR25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1590\/S0041-87812002000500003","volume":"57","author":"FM Silva","year":"2002","unstructured":"Silva FM, Eisig JN, Chehter EZ, Silva JJ, Laudanna AA: Omeprazole, furazolidone, and tetracycline: an eradication treatment for resistant H. pylori in Brazilian patients with peptic ulcer disease. Rev Hosp Clin Fac Med Sao Paulo. 2002, 57: 205-208.","journal-title":"Rev Hosp Clin Fac Med Sao Paulo"},{"key":"916_CR26","first-page":"1545","volume":"85","author":"Y Glupczynski","year":"1990","unstructured":"Glupczynski Y, Burette A: Drug therapy for Helicobacter pylori infection: problems and pitfalls. Am J Gastroenterol. 1990, 85: 1545-1551.","journal-title":"Am J Gastroenterol"},{"key":"916_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1046\/j.1365-2036.2002.01173.x","volume":"16","author":"U Peitz","year":"2002","unstructured":"Peitz U, Sulliga M, Wolle K, Leodolter A, Von Arnim U, Kahl S, Stolte M, Borsch G, Labenz J, Malfertheiner P: High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther. 2002, 16: 315-324. 10.1046\/j.1365-2036.2002.01173.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"916_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/MOG.0b013e32834bb818","volume":"27","author":"M Selgrad","year":"2011","unstructured":"Selgrad M, Malfertheiner P: Treatment of Helicobacter pylori. Curr Opin Gastroenterol. 2011, 27: 565-570. 10.1097\/MOG.0b013e32834bb818.","journal-title":"Curr Opin Gastroenterol"},{"key":"916_CR29","volume-title":"Gut","author":"AE P\u00e9rez-Cobas","year":"2012","unstructured":"P\u00e9rez-Cobas AE, Gosalbes MJ, Friedrichs A, Knecht H, Artacho A, Eismann K, Otto W, Rojo D, Bargiela R, von Bergen M, Neulinger SC, D\u00e4umer C, Heinsen FA, Latorre A, Barbas C, Seifert J, Dos Santos VM, Ott SJ, Ferrer M, Moya A: Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut. 2012, Available at http:\/\/gut.bmj.com\/content\/early\/2012\/12\/11\/gutjnl-2012-303184.long"},{"key":"916_CR30","first-page":"465","volume":"48","author":"S Danese","year":"2001","unstructured":"Danese S, Armuzzi A, Romano A, Cremonini F, Candelli M, Franceschi F, Ojetti V, Venuti A, Pola P, Gasbarrini G: Efficacy and tolerability of antibiotics in patients undergoing H. pylori eradication. Hepatogastroenterology. 2001, 48: 465-467.","journal-title":"Hepatogastroenterology"},{"key":"916_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/j.1365-2036.2001.00923.x","volume":"15","author":"A Armuzzi","year":"2001","unstructured":"Armuzzi A, Cremonini F, Bartolozzi F, Canducci F, Candelli M, Ojetti V, Cammarota G, Anti M, De Lorenzo A, Pola P: The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2001, 15: 163-169. 10.1046\/j.1365-2036.2001.00923.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"916_CR32","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1111\/j.1572-0241.2002.07063.x","volume":"97","author":"F Cremonini","year":"2002","unstructured":"Cremonini F, Di Caro S, Covino M, Armuzzi A, Gabrielli M, Santarelli L, Nista EC, Cammarota G, Gasbarrini G, Gasbarrini A: Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol. 2002, 97: 2744-2749. 10.1111\/j.1572-0241.2002.07063.x.","journal-title":"Am J Gastroenterol"},{"key":"916_CR33","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1345\/aph.1Q104","volume":"45","author":"SM Wilhelm","year":"2011","unstructured":"Wilhelm SM, Johnson JL, Kale-Pradhan PB: Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. Ann Pharmacother. 2011, 45: 960-966. 10.1345\/aph.1Q104.","journal-title":"Ann Pharmacother"},{"key":"916_CR34","doi-asserted-by":"publisher","first-page":"212","DOI":"10.4318\/tjg.2010.0090","volume":"21","author":"B Yasar","year":"2011","unstructured":"Yasar B, Abut E, Kayadibi H, Toros B, Sezikli M, Akkan Z, Keskin O, Ovunc Kurdas O: Efficacy of probiotics in Helicobacter pylori eradication therapy. Turk J Gastroenterol. 2011, 21: 212-217.","journal-title":"Turk J Gastroenterol"},{"key":"916_CR35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1523-5378.2012.00941.x","volume":"17","author":"YJ Yang","year":"2012","unstructured":"Yang YJ, Sheu BS: Probiotics-containing yogurts suppress Helicobacter pylori load and modify immune response and intestinal microbiota in the Helicobacter pylori-infected children. Helicobacter. 2012, 17: 297-304. 10.1111\/j.1523-5378.2012.00941.x.","journal-title":"Helicobacter"},{"key":"916_CR36","doi-asserted-by":"publisher","first-page":"5090","DOI":"10.3748\/wjg.14.5090","volume":"14","author":"C Zhou","year":"2008","unstructured":"Zhou C, Ma FZ, Deng XJ, Yuan H, Ma HS: Lactobacilli inhibit interleukin-8 production induced by Helicobacter pylori lipopolysaccharide-activated Toll-like receptor 4. World J Gastroenterol. 2008, 14: 5090-5095. 10.3748\/wjg.14.5090.","journal-title":"World J Gastroenterol"},{"key":"916_CR37","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/j.1523-5378.2012.00992.x","volume":"17","author":"PS Hsieh","year":"2012","unstructured":"Hsieh PS, Tsai YC, Chen YC, Teh SF, Ou CM, King VA: Eradication of Helicobacter pylori infection by the probiotic strains Lactobacillus johnsonii MH-68 and L. salivarius ssp. salicinius AP-32. Helicobacter. 2012, 17: 466-477. 10.1111\/j.1523-5378.2012.00992.x.","journal-title":"Helicobacter"},{"key":"916_CR38","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1574-695X.2011.00865.x","volume":"63","author":"JM V\u00edtor","year":"2011","unstructured":"V\u00edtor JM, Vale FF: Alternative therapies for Helicobacter pylori: probiotics and phytomedicine. FEMS Immunol Med Microbiol. 2011, 63: 153-164. 10.1111\/j.1574-695X.2011.00865.x.","journal-title":"FEMS Immunol Med Microbiol"},{"key":"916_CR39","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1046\/j.1365-2036.2000.00885.x","volume":"14","author":"F Canducci","year":"2000","unstructured":"Canducci F, Armuzzi A, Cremonini F, Cammarota G, Bartolozzi F, Pola P, Gasbarrini G, Gasbarrini A: A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther. 2000, 14: 1625-1629. 10.1046\/j.1365-2036.2000.00885.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"916_CR40","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1365-2036.2010.04457.x","volume":"32","author":"H Szajewska","year":"2010","unstructured":"Szajewska H, Horvath A, Piwowarczyk A: Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010, 32: 1069-1079. 10.1111\/j.1365-2036.2010.04457.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"916_CR41","first-page":"97","volume":"14","author":"J Zou","year":"2009","unstructured":"Zou J, Dong J, Yu X: Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 2009, 14: 97-107.","journal-title":"Helicobacter"},{"key":"916_CR42","first-page":"251","volume":"12","author":"G Scaccianoce","year":"2008","unstructured":"Scaccianoce G, Zullo A, Hassan C, Gentili F, Cristofari F, Cardinale V, Gigliotti F, Piglionica D, Morini S: Triple therapies plus different probiotics for Helicobacter pylori eradication. Eur Rev Med Pharmacol Sci. 2008, 12: 251-256.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"916_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/MCG.0b013e318266f6cf","volume":"47","author":"ZH Wang","year":"2013","unstructured":"Wang ZH, Gao QY, Fang JY: Meta-Analysis of the Efficacy and Safety of Lactobacillus-containing and Bifidobacterium-containing Probiotic Compound Preparation in Helicobacter pylori Eradication Therapy. J Clin Gastroenterol. 2013, 47: 25-32. 10.1097\/MCG.0b013e318266f6cf.","journal-title":"J Clin Gastroenterol"},{"key":"916_CR44","doi-asserted-by":"publisher","first-page":"740381","DOI":"10.1155\/2012\/740381","volume":"2012","author":"V Ojetti","year":"2012","unstructured":"Ojetti V, Bruno G, Ainora ME, Gigante G, Rizzo G, Roccarina D, Gasbarrini A: Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy. Gastroenterol Res Pract. 2012, 2012: 740381-","journal-title":"Gastroenterol Res Pract"},{"key":"916_CR45","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.3748\/wjg.v18.i43.6302","volume":"18","author":"YQ Du","year":"2012","unstructured":"Du YQ, Su T, Fan JG, Lu YX, Zheng P, Li XH, Guo CY, Xu P, Gong YF, Li ZS: Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection. World J Gastroenterol. 2012, 18: 6302-6307. 10.3748\/wjg.v18.i43.6302.","journal-title":"World J Gastroenterol"},{"key":"916_CR46","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1523-5378.2012.00944.x","volume":"17","author":"M Manfredi","year":"2012","unstructured":"Manfredi M, Bizzarri B, Sacchero RI, Maccari S, Calabrese L, Fabbian F, De'Angelis GL: Helicobacter pylori infection in clinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy. Helicobacter. 2012, 17: 254-263. 10.1111\/j.1523-5378.2012.00944.x.","journal-title":"Helicobacter"},{"key":"916_CR47","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1824-7288-38-63","volume":"38","author":"S Tolone","year":"2012","unstructured":"Tolone S, Pellino V, Vitaliti G, Lanzafame A, Tolone C: Evaluation of Helicobacter Pylori eradication in pediatric patients by triple therapy plus lactoferrin and probiotics compared to triple therapy alone. Ital J Pediatr. 2012, 38: 63-10.1186\/1824-7288-38-63.","journal-title":"Ital J Pediatr"},{"key":"916_CR48","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1046\/j.1365-2036.2003.01452.x","volume":"17","author":"A Cats","year":"2003","unstructured":"Cats A, Kuipers EJ, Bosschaert MA, Pot RG, Vandenbroucke-Grauls CM, Kusters JG: Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment Pharmacol Ther. 2003, 17: 429-435. 10.1046\/j.1365-2036.2003.01452.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"916_CR49","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1440-1746.2010.06477.x","volume":"26","author":"H Yoon","year":"2011","unstructured":"Yoon H, Kim N, Kim JY, Park SY, Park JH, Jung HC, Song IS: Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection. J Gastroenterol Hepatol. 2011, 26: 44-48.","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"916_CR50","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1523-5378.2009.00700.x","volume":"14","author":"A Kindermann","year":"2009","unstructured":"Kindermann A, Lopes AI: Helicobacter pylori infection in pediatrics. Helicobacter. 2009, 14 (Suppl 1): 52-57.","journal-title":"Helicobacter"},{"key":"916_CR51","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s10096-010-1119-4","volume":"30","author":"JA Medeiros","year":"2011","unstructured":"Medeiros JA, Goncalves TM, Boyanova L, Pereira MI, de Carvalho JN, Pereira AM, Cabrita AM: Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone. Eur J Clin Microbiol Infect Dis. 2011, 30: 555-559. 10.1007\/s10096-010-1119-4.","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-230X-13-56\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-13-56.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-13-56","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-13-56.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:23:25Z","timestamp":1715127805000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/1471-230X-13-56"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,26]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["916"],"URL":"https:\/\/doi.org\/10.1186\/1471-230x-13-56","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,26]]},"article-number":"56"}}